BriaCell Therapeutics Corp.: Form 10-K for the period ended Jul 31, 2022
Filed with the SEC on Oct 28, 2022 and accepted by EDGAR at Oct 27, 2022, 18:00 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-07-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2021-08-01 to 2022-07-31 | $8.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2021-08-01 to 2022-07-31 | −$15.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2021-08-01 to 2022-07-31 | $979 | us-gaap:InterestExpense |
| Net income | 12 months2021-08-01 to 2022-07-31 | −$26.8m | us-gaap:NetIncomeLoss |
| Basic EPS | 12 months2021-08-01 to 2022-07-31 | −$1.73 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 12 months2021-08-01 to 2022-07-31 | −$12.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2022-07-31 | $41.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-07-31 | $42.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-07-31 | $42.6m | us-gaap:Assets |
| Current liabilities | At period end2022-07-31 | $941.1k | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2022-07-31 | $10.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-22-029742. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.